Maraviroc, a CCR5 Coreceptor Antagonist That Blocks Entry of Human Immunodeficiency Virus Type 1

Suppression of Dualtropic Human Immunodeficiency Virus Type 1 by the CXCR4 Antagonist AMD3100 Is Associated with Efficiency of CXCR4 Use and Baseline Virus Composition

(2008) S. Fransen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers

(2008) Y. J. Cao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects

(2008) John D. Davis et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

(2008) Samantha Abel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

(2008) Samantha Abel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection

(2008) Sharon S. Lieberman-Blum et al.   CLINICAL THERAPEUTICS